Marker Therapeutics, Inc.

Monthly Archives: January 2018

Breast Cancer Vaccine Candidate Launches Phase 2 Clinical Study

Precision Vaccination highlighted our cancer vaccine, TPIV200 for treating triple-negative breast cancer.

Read More

Cancer Vaccine to Prevent Breast, Ovarian Cancer Recurrence Could be Close

Peter Hoang, President and CEO of TapImmune, is enthusiastic about a cancer vaccine under development by TapImmune that could help prevent recurrence of such cancers in women.

Read More

TapImmune Brings Therapeutic Vaccines into the Clinic for Ovarian, Breast Cancer

With new innovations and breakthroughs in the field of immunotherapy TapImmune CEO & President, Peter Hoang has been amazed by the change of pace within the field.

Read More

TapImmune to Present at Biotech Showcase™ 2018

TapImmune President & CEO, Peter Hoang, to present at Biotech Showcase next week.

Read More